Amundi Buys 3,742 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Amundi increased its Regeneron position by 3,742 shares in the second quarter, bringing its holdings to 1,013,540 shares valued at approximately $632 million. Institutional investors own 83.31% of the company.
• Regeneron reported strong quarterly results, with earnings of $14.29 per share and revenue of $4.29 billion, both exceeding analyst expectations. Analysts maintain a “Moderate Buy” consensus rating, with an average price target of $800.36.
• Insiders sold shares worth roughly $3.43 million over the past 90 days under pre-arranged Rule 10b5-1 plans. Investors also face potential legal and pipeline risks related to allegations surrounding the Phase 3 Fianlimab-Libtayo trial.

Amundi lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 0.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,013,540 shares of the biopharmaceutical company's stock after purchasing an additional 3,742 shares during the quarter. Amundi owned 0.98% of Regeneron Pharmaceuticals worth $631,983,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the stock. SHP Wealth Management bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth $26,000. Western Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $26,000. Titan Wealth CI Ltd purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth $29,000. Trust Co. of Vermont acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $29,000. Finally, Mowery & Schoenfeld Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter worth $29,000. 83.31% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 31.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of the firm's stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total value of $969,708.09. Following the sale, the executive vice president directly owned 12,003 shares of the company's stock, valued at $10,291,252.17. The trade was a 8.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 4,146 shares of company stock valued at $3,432,488 over the last 90 days. Insiders own 6.97% of the company's stock.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Recent commentary continues to view Regeneron as a potentially attractive long-term biotech investment, supported by its established commercial portfolio, development pipeline and strong financial profile. However, the comparison with Vertex reportedly gives Vertex the clearer near-term investment edge. Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
• Neutral Sentiment: Regeneron’s Phase 1/2 study combining cemiplimab with SNS-101 has been completed, providing a pipeline milestone, although no efficacy or regulatory results were released. Cemiplimab Combination Trial Completion
• Negative Sentiment: Several law firms are recruiting investors for a securities class action alleging that Regeneron and certain executives misled shareholders about the viability and risks of the Phase 3 Fianlimab-Libtayo trial, including its protocol change and failure to meet the primary endpoint. Investors have until September 14, 2026, to seek lead-plaintiff status. The allegations have not been proven, but the litigation creates potential reputational, legal and financial risks. Regeneron Class Action Deadline Alert
• Negative Sentiment: Director Kathryn Guarini sold 400 shares for $340,000, while EVP Marion McCourt sold 2,346 shares for approximately $2.0 million. All sales were made under pre-arranged Rule 10b5-1 plans, reducing their value as discretionary bearish signals, but the transactions may weigh on sentiment near recent highs. SEC Insider Transaction Filing

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $827.72 on Monday. The stock has a market capitalization of $85.22 billion, a P/E ratio of 20.46, a PEG ratio of 1.62 and a beta of 0.20. The business has a 50 day simple moving average of $738.29 and a two-hundred day simple moving average of $719.51. Regeneron Pharmaceuticals, Inc. has a 12 month low of $541.00 and a 12 month high of $859.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm had revenue of $4.29 billion during the quarter, compared to analysts' expectations of $3.82 billion. During the same period in the previous year, the business earned $12.81 earnings per share. The firm's revenue for the quarter was up 16.7% on a year-over-year basis. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were issued a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend was Tuesday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 9.29%.

Analyst Upgrades and Downgrades

Several research firms have commented on REGN. Wells Fargo & Company upped their price objective on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an "equal weight" rating in a research report on Friday, July 31st. Citigroup increased their target price on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a "neutral" rating in a research note on Monday, August 3rd. Truist Financial lifted their price target on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a "buy" rating in a research note on Friday, July 31st. Guggenheim upped their price target on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a "buy" rating in a report on Monday, August 3rd. Finally, Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an "overweight" rating on the stock in a research report on Thursday, July 9th. Fourteen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $800.36.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source